Despite advances in our understanding of breast cancer, patients with metastatic disease have poor prognoses. GATA3 is a transcription factor that specifies and maintains mammary luminal epithelial cell fate, and its expression is lost in breast cancer, correlating with a worse prognosis in human patients. Here, we show that GATA3 promotes differentiation, suppresses metastasis and alters the tumour microenvironment in breast cancer by inducing microRNA-29b (miR-29b) expression. Accordingly, miR-29b is enriched in luminal breast cancers and loss of miR-29b, even in GATA3-expressing cells, increases metastasis and promotes a mesenchymal phenotype. Mechanistically, miR-29b inhibits metastasis by targeting a network of pro-metastatic regulators involved in angiogenesis, collagen remodelling and proteolysis, including VEGFA, ANGPTL4, PDGF, LOX and MMP9, and targeting ITGA6, ITGB1 and TGFB, thereby indirectly affecting differentiation and epithelial plasticity. The discovery that a GATA3-miR-29b axis regulates the tumour microenvironment and inhibits metastasis opens up possibilities for therapeutic intervention in breast cancer.
One of the classical hallmarks of cancer is the ability for tumour cells to invade and metastasize 1 . Metastasis is a multi-stage process that includes extracellular matrix remodelling, blood vessel recruitment, tumour cell entry and exit from circulation, and survival at a distant organ 2 . The tumour microenvironment is increasingly recognized as an important contributor to malignant progression and metastasis 3, 4 . In addition to remodelling the microenvironment to facilitate metastasis, cancer cells also turn on embryonic morphogenesis regulators to undergo the epithelial-to-mesenchymal transition (EMT) and turn off differentiation programs 5 , allowing cancer cells to gain motility, modify cell adhesion and acquire stem-like properties 6 . In contrast to EMT, differentiation is associated with less aggressive tumours and better prognosis. GATA3 is a transcription factor that specifies and maintains luminal epithelial cell differentiation in the mammary gland [7] [8] [9] . Loss of GATA3 is involved in breast cancer pathogenesis [8] [9] [10] and a low GATA3 level is associated with poor prognosis [11] [12] [13] . Mutations in GATA3 that diminish or abolish its DNA-binding ability are commonly found in human breast cancers, and GATA3 was recently found to be one of three genes mutated in >10% of all breast cancers 14, 15 . In several mouse models of breast cancer, Gata3 expression inversely correlates with tumour and reduces tumour-initiating capacity 16 . However, how GATA3 induces tumour differentiation and inhibits dissemination, and what molecular and cellular events lie downstream of GATA3 are unknown.
MicroRNAs (miRNAs) are small, non-coding RNAs that modulate gene expression post-transcriptionally, either by inhibiting translation or by causing degradation through binding to the 3 untranslated regions (UTRs) of target messenger RNAs (ref. 17) . miRNAs are both positive and negative regulators of cancer metastasis [18] [19] [20] . Precedence for GATA-mediated miRNA regulation has recently been established: GATA1 promotes erythrocyte differentiation through miR-451, suggesting that GATA factors use miRNAs to make cell fate decisions 21 . In the mammary gland, miRNAs such as let-7 promote mammary differentiation and regulate self-renewal 22, 23 . However, miRNAs downstream of GATA3 have yet to be investigated.
In this study, we predicted that GATA3 coordinates gene expression networks involved in metastasis through miRNA-mediated mechanisms. We investigated the molecular pathways by which GATA3 regulates differentiation and metastasis, and identified miR-29b, a miRNA downstream of GATA3 that modulates the tumour microenvironment, metastasis and epithelial plasticity.
RESULTS

GATA3 suppresses lung metastases from human and mouse breast cancer
Human breast cancers are classified into several subtypes that are prognostic of outcome 24 . Clinically, basal, triple-negative breast cancers are more aggressive and poorly differentiated 25 . In human breast cancer lines 26 , GATA3 is expressed at a higher level in luminal versus basal A and basal B subtypes (Fig. 1a) , consistent with its luminal localization ( Supplementary Fig. S1a ).
We overexpressed mouse Gata3 in basal 4T1 cells to evaluate metastasis in an immunocompetent model, and human GATA3 in basal MDA-MB-231 cells (referred to as MDA231), lines with low endogenous GATA3 (Fig. 1b and Supplementary Figs S1b,c and S2a,b). Orthotopic transplant of stably transduced 4T1-Gata3 cells into BALB/c mice gave rise to tumours similar in size to 4T1-Control cells, but showed a significant decrease in the number and size of spontaneous lung metastases ( Fig. 1c-f) . Interestingly, whereas primary 4T1-Gata3 tumours expressed GATA3, the lung metastases were mostly GATA3-low ( Fig. 1g and Supplementary Fig. S1d ), suggesting that metastatic cells lost GATA3 expression. We did not observe any difference in proliferation in vivo or in culture ( Supplementary Fig. S1e ,f), suggesting that GATA3 causes no intrinsic defects on viability, and that the difference in metastasis depends on in vivo microenvironment interactions. Indeed, 4T1-Gata3 tumours exhibited significant decreases in tumour vasculature and macrophage infiltrates (Fig. 1h,i) . Consistent with this, we found a twofold reduction in serum VEGF-A levels in mice bearing orthotopic 4T1-Gata3 primary tumours ( Supplementary Fig. S1g ), suggesting that GATA3 regulates VEGF-A in vivo.
Human MDA231-GATA3 cells injected into nude mice formed smaller tumours than MDA231-Control cells, with decreased tumour vasculature and macrophage infiltrates and secreted less VEGF-A ( Supplementary Fig. S2c-g ). MDA231-GATA3 cells showed no difference in proliferation in culture or in viable tumour areas, but expressed higher levels of apoptotic markers and exhibited more necrosis in vivo ( Supplementary Fig. S2h-k) . These data support the concept that microenvironment interactions are critical for GATA3-mediated metastasis inhibition.
We next examined whether GATA3 only limits the ability of tumour cells to disseminate from the primary site, or if it also affects the later stages of metastasis, for example, colonization. Accordingly, we inoculated the cells directly into the circulation by intravenous (i.v.) injection (through the tail vein) to form experimental metastases. For both 4T1 and MDA231 cells, GATA3 decreased lung metastases ( Fig. 1j and Supplementary Fig. S2l ). We validated that these experimental metastases maintained GATA3 overexpression (Fig. 1k) . Thus, sustained GATA3 expression also inhibits the late steps of metastasis.
To determine whether GATA3-expressing cells can compete with control cells, we labelled 4T1 cells with RFP (control) or Gata3-GFP, mixed them in a 1:1 ratio, and co-injected them i.v. After 2 weeks, we found that 4T1-Gata3-GFP cells accounted for only ∼20% of the total metastatic cells in the lung, whereas 4T1-RFP cells accounted for ∼80% (Fig. 1l) . These results indicate that GATA3 confers a competitive disadvantage in vivo.
GATA3 promotes differentiation and limits cell migration
As GATA3 regulates luminal fate, we sought to determine whether GATA3-mediated metastasis suppression involves cell differentiation. In two-dimensional cell culture, MDA231-Control cells had a more spindle-shaped, mesenchymal morphology, whereas MDA231-GATA3 cells exhibited a more epithelial phenotype (Fig. 2a) . In a woundscratch assay, MDA231-Control cells migrated as single cells to close the wound, whereas MDA231-GATA3 cells migrated as a collective sheet (Supplementary Fig. S3a ). In three-dimensional (3D) Matrigel culture, which better mimics physiological conditions 27, 28 , GATA3-overexpressing MDA231 and Hs578T human basal cells were less invasive than their controls ( Fig. 2b and Supplementary Fig. S3b-d and Videos S1 and S2).
Using quantitative PCR (qPCR), we found that GATA3 increased the level of expression of luminal genes and decreased the level of expression of basal, EMT, stemness and inflammatory genes ( Fig. 2c and Supplementary Fig. S3e ,f). Despite these gene expression changes, 4T1-Gata3 cells were morphologically similar to 4T1-Control cells ( Supplementary Fig. S3g ). GATA3 also induced basal cells to adopt a luminal cell surface phenotype characterized by decreased CD49f (integrin α6) and increased EpCAM expression 29 ( Fig. 2d-f) . Furthermore, MDA231-GATA3 and 4T1-Gata3 cells formed fewer, smaller and less invasive tumour spheres from single cells (Fig. 2g,h and Supplementary  Fig. S3h ). Taken together, these results indicate that GATA3 promotes a luminal differentiation program and opposes the basal/EMT state.
GATA3 promotes miR-29b expression
In addition to the cell-intrinsic effects of GATA3 on differentiation, we were intrigued by the observation that GATA3-expressing tumours had reduced serum VEGF-A and tumour vasculature. However, the VEGFA promoter lacked clear GATA3-binding sites, and GATA3 did not decrease the activity of a luciferase reporter containing the VEGFA promoter ( Supplementary Fig. S3i ). We therefore reasoned that GATA3 regulates VEGFA and perhaps other pro-metastatic genes indirectly through miRNAs and conducted a screen in MDA231 cells ± GATA3 using qPCR miRNA arrays. Of 88 miRNAs evaluated, miR-29b was the most upregulated miRNA in MDA231-GATA3 cells (Fig. 3a,b and Supplementary Table S1), and the expression level of miR-29b was also increased in Hs578T-GATA3 cells ( Supplementary  Fig. S4a ). The miR-29 family consists of three members with the same seed sequence: miR-29a, miR-29b and miR-29c ( Supplementary Fig.  S4b ). We also found that miR-29a and miR-29c were increased by GATA3 ( Supplementary Fig. S4c ), with miR-29a being ∼400-fold more abundant than miR-29c at basal levels.
The miR29a/b1 promoter, which was previously identified 30 , contains three GATA3-binding sites ( Supplementary Fig. S4d ). GATA3 increased the activity of the miR29a/b1-promoter reporter (Fig. 3c) , and deleting the GATA sites diminished GATA3-mediated reporter induction, demonstrating that these sites are necessary and functional (Fig. 3d) .
As previous studies showed that miR-29b is negatively regulated by TGF-β and NF-κB (refs 30-32) we also examined whether GATA3 inhibits the TGF-β and NF-κB pathways, thereby regulating miR-29b indirectly. Indeed, GATA3 inhibited TGF-β and NF-κB reporter activities and suppressed TGF-β-induced EMT and components of the TGF-β pathway transcriptionally (Fig. 3e,f and Supplementary  Fig. S4e-g ). Stimulation with recombinant TGF-β, TNF-α or sRANKL decreased miR-29a and miR-29b levels in control, but not GATA3, cells ( Supplementary Fig. S4h,i) . Thus, GATA3 induces miR-29b expression directly (by binding the GATA sites on the promoter) and indirectly (by inhibiting the TGF-β and NF-κB pathways). 
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CD49f-PE . ( * P < 0.01 by probability binning χ 2 test.) (g,h) Number of tumour spheres from single MDA231 cells ± GATA3 ( * P < 0.02; g), and representative phase-contrast images (h) of n = 3 independent experiments performed in triplicate. Data are reported as mean ± s.e.m. All scale bars, 100 µm.
miR-29 expression is enriched in more differentiated breast cancer and normal luminal epithelial cells
We examined whether miR-29 correlates with more differentiated breast cancers, which are associated with better patient outcomes 12 . In an miRNA data set of 99 primary human breast tumours 33 , the levels of all three miR29 members were higher in luminal and oestrogen-receptor-positive (ER+) tumours (Fig. 3g,h ). Moreover, miR-29c was associated with more favourable prog- noses in a meta-analysis of over 1,000 breast cancers 34 and with luminal differentiation in an independent data set of over 100 human breast tumours 35 .
We then used a miRNA data set of mouse breast tumours 36 and found that miR-29 members were expressed at higher levels in luminal when compared with basal models (Fig. 3i) . In normal epithelial cells isolated from the mouse mammary gland, all miR-29 members were expressed at higher levels in the luminal fraction ( Supplementary Fig. S5a-c) .
We next examined whether miR-29b is inversely related to metastatic ability. Using a data set of syngeneic cell lines with varying metastatic capabilities 37, 38 , we found that expression of miR-29b was lowest in cells with the highest metastatic capacities (Fig. 3j and Supplementary  Fig. S5d ). In the MMTV-PyMT model, which mimics progressive stages of human luminal breast cancer 39 , adenoma and carcinoma cells had decreased Gata3 and miR-29b expression levels compared with normal epithelium (Fig. 3k) , with the lowest levels at the carcinoma stage coinciding with metastasis. Together, these results demonstrate that miR-29 expression correlates with more favourable outcomes, more differentiated phenotypes in normal and cancer cells and reduced metastatic potential.
miR-29b promotes and maintains luminal differentiation
We next examined whether miR-29b promotes luminal characteristics. MMTV-PyMT tumours become less differentiated during tumour progression 39 . Stable overexpression of miR-29b in a primary cell line derived from a late-stage MMTV-PyMT carcinoma resulted in a more epithelial phenotype, higher luminal marker and lower basal marker expression levels (Fig. 4a,b) . In addition, miR-29b promoted branching of PyMT cell aggregates in 3D Matrigel (Fig. 4c) , a feature of normal branching morphogenesis 40 . We then examined whether loss of miR-29b induces a dedifferentiated, mesenchymal phenotype. We generated miR-29b-knockdown cells using miR-Zip29b lentiviruses, which stably knockdown endogenous miRNAs. Although miR-29b levels decreased as expected, we also observed decreases in miR-29a and miR-29c levels, probably owing to their similar sequences ( Supplementary Fig. S6a,d ). MDA231-Zip29 cells were more elongated, protrusive and spindle-like, expressed lower GATA3 and had increased levels of CD49f and CD29 (Fig. 4d,e and Supplementary Fig. S6b ), two markers of the basal/stem cell population that have miR-29b-binding sites. Loss of miR-29b in mouse 4TO7 cells also caused a spindle-like morphology and increased mesenchymal marker levels ( Supplementary Fig. S6c,d) .
We extended our findings to normal human mammary cells (HMLE), which exhibit phenotypic plasticity in vitro 6 . HMLE-Zip29 cells were more elongated and spindle-like and had increased mesenchymal and decreased epithelial marker expression levels. The EMT program has previously been linked to stem-like traits 6 . Loss of miR-29b increased the CD44 hi /CD24 low stem-cell-enriched compartment and increased the level of stem cell marker expression (Fig. 4f-i and Supplementary  Fig. S6e,f) . Loss of miR-29 also increased basal/stem cell markers in PyMT and 4T1 cells ( Supplementary Fig. S6g-j) .
HMLE-Zip29 cells had higher basal levels of phospho-Smad3 (Fig. 4i) , suggesting that miR-29b knockdown increases unchecked TGF-β signalling, which promotes EMT. Consistent with this, inhibiting TGF-β signalling using LY-364947 in HMLE-Zip29 cells reversed the increased CD44 hi /CD24 low population (Fig. 4j) . Taken together, these results indicate that miR-29b promotes differentiation, and loss of miR-29b causes de-differentiation and increases the level of mesenchymal marker expression characteristic of a progenitor-like state, which is mediated, at least in part, by an increased level of TGF-β signalling.
miR-29b downregulates pro-metastatic genes that modify the tumour microenvironment and indirectly regulate epithelial plasticity We used prediction algorithms to generate a list of candidate miR-29b targets [41] [42] [43] . Although transcription factors associated with EMT (for example, SNAI1, TWIST or ZEB1) did not have miR-29b-binding sites in their 3 UTRs, TGFB, a potent inducer of EMT and de-differentiation contained miR-29b-binding sites (Fig. 5a ). In addition, ITGA6 (CD49f) and ITGB1 (CD29), which maintain and enhance stemness 44 and are commonly used markers to identify the basal population, contained miR-29b-binding sites in their 3 UTRs. Interestingly, we identified miR-29b sites in many microenvironmental genes involved in angiogenesis, collagen remodelling and matrix degradation, including ANGPTL4, LOX, MMP2, MMP9, PDGF and VEGF (Fig. 5a) , which have been implicated in promoting metastasis 4, 45 . To determine whether miR-29b modulates these genes directly, we cloned these 3 UTRs into luciferase reporters and co-transfected them with either miR-29b or control mimic. For all 3 UTRs tested, miR-29b decreased luciferase activity by 40-80% (Fig. 5b) , which was partially relieved when the miR-29b sites were mutated (Fig. 5c ), indicating that these sites are functional and specific for miR-29b.
We stably transduced 4T1 and MDA231 cells with miR-29b and confirmed its overexpression (Fig. 5d) . In both 4T1 and MDA231 cells, miR-29b repressed endogenous mRNA levels of target genes ( Fig. 5e and Supplementary Fig. S7a,b) . We validated a subset of targets at the protein level by western blot and cell surface staining, and found that miR-29b decreased the levels of ANGPTL4, ITGA6 (CD49f), LOX and VEGF-A (Fig. 5f,g ). These results suggest that miR-29b downregulates a cohort of pro-metastatic genes involved in differentiation and modifying the tumour microenvironment.
miR-29b expression suppresses lung metastasis
To determine whether miR-29b suppresses metastasis, we injected mice with 4T1-Control or 4T1-miR-29b cells orthotopically. Although there was no difference in primary tumour size, 4T1-miR-29b tumours had significantly fewer blood vessels and a decreased level of fibrillar collagen (Fig. 6a-c) . Importantly, mice with 4T1-miR-29b tumours had fewer and smaller metastases (Fig. 6d) . miR-29b also significantly reduced the size and number of experimental lung metastases in both 4T1 and MDA231 cells (Fig. 6e and Supplementary Fig. S7c-e) .
As miR-29b levels decrease during tumour progression in MMTVPyMT mice, we examined whether any miR-29b targets increase in parallel. In carcinomas, where miR-29b levels were lowest, the expression level of many miR-29b targets increased (Fig. 6f) . Moreover, PyMT-miR-29b cells showed decreased target expression levels ( Supplementary Fig. S7f-h ) and significantly reduced lung metastasis (Fig. 6g,h) . Conversely, loss of miR-29b in PyMT, 4T1 and MDA231 cells increased spontaneous and experimental lung metastases and EMT markers in vivo (Fig. 6i,j and Supplementary Fig. S8a-f) . Taken together, these results show that miR-29b functions as a metastasis suppressor in human and mouse models of breast cancer.
miR-29b suppresses metastasis by repressing microenvironmental targets
To gain further insight into how miR-29b suppresses metastasis, we examined whether the levels of miR-29b targets increase after miR-29 0.8 knockdown. Many miR-29b targets we identified were upregulated after miR-29 loss, including ANGPTL4, LOX, MMP9, VEGFA, ITGA6 and ITGB1 (Figs 7a and 4e) . Moreover, miR-29 knockdown increased the level of 3 UTR luciferase reporters of miR-29b targets (Fig. 7b) , further validating these as bona fide targets. We examined whether restoring the expression of four miR-29b targets, with known roles in angiogenesis and ECM remodelling, would increase metastasis. miR-29b alone inhibited metastasis, and re-expression of ANGPTL4, LOX, MMP9 or VEGF-A in 4T1-miR-29b cells restored lung metastasis (Fig. 7c,d ), indicating that miR-29b suppresses metastasis, at least in part, by regulating these microenvironmental genes.
Regulation of miR-29b mediates the ability of GATA3 to suppress metastasis and promote differentiation
To determine whether GATA3-mediated metastasis suppression and differentiation requires miR-29b, we knocked down miR-29b in MDA231-GATA3 cells. GATA3 overexpression promoted epithelial clustering, and concomitant loss of miR-29b abrogated the effects of GATA3, resulting in elongated, spindle-like cells (Fig. 8a) . Similarly, mice were injected with 4T1 cells ± Gata3 ± Zip29 into the mammary fat pad. Tumours were allowed to grow for four weeks and lungs were examined for spontaneous metastases (e). Representative H&E images are shown (f).
(n = 10 independent mice per group, * P < 0.05.) (g,h) BALB/c mice were injected i.v. with 4T1 cells ± Gata3 ± Zip29 knockdown and euthanized two weeks post injection. The number of lung surface metastases was quantified (g) and immunofluorescence staining was performed for E-cadherin (green) and vimentin (red; h; n = 8 independent mice per group, * * P < 0.01). loss of miR-29 in T47D luminal breast cancer cells, which highly express endogenous GATA3, caused a mesenchymal morphology accompanied by an increase in the levels of EMT markers and target expression ( Supplementary Fig. S8g-i) . Thus, tumour cells acquire mesenchymal characteristics in the absence of miR-29b, even with high levels of GATA3 expression. We examined whether GATA3 downregulated miR-29b targets, and found that the levels of expression and 3 UTR reporters of miR-29b targets, including ANGPTL4, LOX, MMP9 and VEGFA, were decreased by GATA3; this inhibition was partially reversed in GATA3-Zip29 cells (Fig. 8b,c) . Significantly, we found that miR-29 knockdown reversed GATA3-mediated suppression of experimental and spontaneous metastases and increased the vimentin expression level (Fig. 8d-h and Supplementary Fig. S8j ), indicating that perturbation of miR-29b attenuates the anti-metastatic and pro-differentiation functions of GATA3. Together, our results demonstrate that miR-29b is an important node downstream of GATA3 that controls differentiation and the expression of pro-metastatic genes involved in modifying the tumour microenvironment, ultimately leading to metastasis suppression (Fig. 8i) .
DISCUSSION
In this study, we show that GATA3 promotes luminal differentiation and suppresses lung metastasis through miR-29b, an anti-metastatic microRNA that promotes differentiation and regulates the tumour microenvironment (Fig. 8g) . We demonstrate that GATA3 increases the level of expression of miR-29b, which is exquisitely positioned to inhibit several steps required for metastasis: a network of mRNAs involved in stemness/EMT, angiogenesis, proteolysis, ECM signalling and ECM remodelling have miR-29b-binding sites and are bona fide miR-29b targets. Although we did not find miR-29b sites in classical EMT-promoting transcription factors, ITGA6 (CD49f) and ITGB1 (CD29), markers of the basal/stem cell population previously implicated in maintaining and enhancing stemness 44 , and TGFB2 and TGFB3, all had miR-29b-binding sites. As miRNAs act pleiotropically and modulate a range of biological processes, they represent an ideal set of targets through which transcription factors such as GATA3 can operate.
The loss of GATA3 triggers fibroblastic transformation and cell invasion 46 , and coincides with the onset of angiogenesis, inflammatory cell recruitment, and dissemination 10 . It has been shown that GATA3 reduces tumour vasculature and macrophage infiltrates, components of the tumour microenvironment that promote metastasis 16, 47 . In human breast cancer, GATA3 correlates with higher E-cadherin and ER expression levels 13 . These observations suggest that promoting differentiation in primary tumours limits metastasis by both non-cellautonomous mechanisms (for example, angiogenesis, inflammation, ECM remodelling) and cell-autonomous mechanisms (for example, increased cell adhesion). In breast cancer, the level of miR-29b expression is highest in good prognostic, well-differentiated, luminal-type cancers and inhibits metastasis, the main cause of cancer-related deaths. miR29b promoted luminal differentiation; conversely, loss of miR-29b promoted mesenchymal traits and metastasis. Concomitant loss of miR-29b in GATA3-expressing cells restored metastasis and abrogated the ability of GATA3 to promote differentiation, indicating that miR-29b is an important node that exerts its anti-metastatic effects by cell-intrinsic and cell-extrinsic mechanisms. We found that miR-29b-mediated metastasis inhibition depended on repression of its targets. Of these, ANGPTL4 affects lung seeding by disrupting endothelial cell junctions 45 ; LOX increases tissue fibrosis and integrinmediated survival signalling 48 ; MMP9 remodels the ECM and releases sequestered VEGF-A (ref. 49); and VEGF-A promotes angiogenesis. Interestingly, dysregulation of the miR-29 family has been implicated in tissue fibrosis [50] [51] [52] and many cancers, including leukaemia, lung cancer, liver cancer, rhabdomyosarcoma and melanoma 32, [53] [54] [55] . TGF-β signalling activates the promoters of many of the same genes that are miR-29b targets, including LOX, MMPs and VEGFA (refs 56-58) , and is a potent inducer of EMT. We found that GATA3 inhibited TGF-β and that TGFB2 and TGFB3 are miR-29b targets. Therefore, to repress TGF-β-induced activation of its target genes, GATA3 inhibits the signalling network directly at the transcriptional level and indirectly at the post-transcriptional level through miR-29b (that is, degradation and translational inhibition of already-made TGFB mRNAs). This multi-tiered system ensures efficient GATA3-mediated inhibition of TGF-β signalling. Interestingly, miR-29b also increased GATA3, and loss of miR-29b decreased GATA3, suggesting that GATA3 and miR-29b form a positive feedback loop and act collaboratively to reinforce fate decisions. The exact mechanisms of how GATA3 and miR-29b function in cell-type-specific manners remain to be further investigated.
Our work on miR-29b adds to the growing body of evidence implicating miRNA-mediated regulation of cancer and the tumour microenvironment. Previous studies have shown that many microRNAs play important pro-and anti-metastatic roles by regulating diverse cellular processes used during metastasis 20, 59, 60 . Future work aimed at identifying other GATA3 targets and determining their function will allow us to further understand the role of GATA3 in development and cancer.
Rather than functioning as a classical tumour suppressor, GATA3 defines a distinct class of pro-differentiation factors capable of also modifying the tumour microenvironment. The identification of one GATA3 target, miR-29b, illustrates how epithelial plasticity, the tumour microenvironment and metastasis are linked. Finally, miRNAs are being pursued as potential anti-cancer agents 61, 62 . Whether increasing miR-29b levels in primary breast tumours improves patient survival will ultimately determine the therapeutic use of miR-29b mimics.
METHODS
Methods and any associated references are available in the online version of the paper. For primary tumours and spontaneous metastasis assays, age-matched female mice were injected with the indicated number of cells in 1:1 DMEM/Matrigel (BD Biosciences) into the fourth mammary fat pad without clearing. Tumour measurements were made blinded, using a caliper at least once per week, and volumes were calculated using the formula: V = 0.52×(length) 2 ×width. Bioluminescence imaging was performed using an IVIS Spectrum and image radiance values were normalized using Living Image (Caliper LifeScience).
Cell culture. MDA-MB-231, T47D, Hs578T, HEK293T, GP2, 4T1 and 4TO7 cells were obtained from the ATCC, LBNL or UCSF Cell Culture Facility, and grown in standard conditions (DMEM with 10% FBS). The immortalized human mammary epithelial cells (HMLE) were obtained from J. Debnath (UCSF, San Francisco, CA) and W. Hahn (Harvard University, USA) and maintained in MEGM (Lonza) as previously described 63 . The PyMT cell line was generated by isolating a late-stage MMTV-PyMT/FVB tumour, dissociating the cells in collagenase, and culturing in DMEM/F12 media supplemented with 5% FBS, insulin and hydrocortisone. For TGF-β stimulation, cells were serum-starved for 18-24 h before adding TGF-β1 or TGF-β2 (R&D Systems) at 5 ng ml −1 . For TGF-βR inhibition, cells were grown in standard conditions with 10 µm LY-364947 (Calbiochem) or dimethylsulphoxide (Sigma). For cells embedded in Matrigel, cells were aggregated overnight on ultralow attachment plates (Corning) and then embedded into growth-factorreduced Matrigel (BD Biosciences) the next day. Cells were grown in serum-free media supplemented with insulin-transferrin (Invitrogen) and 50 ng ml −1 of EGF (Invitrogen) or 2.5 nM FGF2 (Sigma).
Lentiviral and retroviral production. Viral production was carried out using calcium-phosphate-mediated transfection of HEK293T or GP2 cells. Virus was concentrated by ultracentrifugation, and added to cells with Polybrene. Stably transduced cells were selected in puromycin, G418 or hygromycin for at least 5 days or selected by FACS.
